Возможности применения бета-адреноблокаторов при артериальной гипертензии


Мельник М.В., Шилов А.М.

В статье рассматриваются вопросы использования beta-адреноблокаторов в лечении артериальной гипертензии (АГ). Приводятся данные исследования по использованию кардиоселективного бета-адреноблокатора Бисогаммы (бисопролола) в лечении АГ у 48 пациентов, согласно которым обсуждаемый препарат доказал метаболическую нейтральность, способность улучшать реологические свойства крови и препятствовать прогрессированию изменений со стороны артериального русла у больных данной группы.

Литература


1. Rose G. Sick individuals and sick populations. Int J Epidemiol 2001;30:427–32.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003;42:1206–52.
3. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–92.
4. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–87.
5. Диагностика и лечение артериальной гипертензии, Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов, приложение 2 к журналу “Кардиоваскулярная терапия и профилактика”. 2008. № 7(6).
6. Карпов Ю.А. Европейские рекомендации по артериальной гипертонии – главное событие 2007 года // РМЖ. 2007. № 20. C. 1405–8.
7. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS–IV): summary. BMJ 2004;328:634–64.
8. Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292(19):2343–49.
9. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as rquired, in the Anglo–Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.
10. Williams B, Lacy PS, Thom SM, et al.CAFE Investigators; Anglo– Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–25.
11. Morgan T. Effect of different antihypertensive drug classes on central aortic pressure. / T.Morgan, J. Lauri, D. Bertram, A. Anderson. Am J Hypertens 2004;17:118–23.
12. Hirata K, Vlachopoulos C, Adji A, et al. Benefits from angiotensin– converting enzyme inhibitor “beyond blood pressure lowering” beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551–56.
13. London GM, Asmar RG, O’Rourke MF, et al.Mechanism(s) of selective systolic blood pressure reduction after a low–dose combination ofperindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92–9.
14. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double–blind study (BISOMET). Eur Heart J 1987;8:103–13.
15. Gosse P, Roudaut R, Herrero G, et al. Beta–blockers vs angiotensin–converting enzyme inhibitors in hypertension: effects of left ventricular hypertrophy. J Cardiovasc Pharmacol 1990;16(5):145–50.
16. Prisant LM, Weir MR, Frishman WH, et al. Self Reported Sexual Dysfunction in Men and Women Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Amlodipine, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich). 1999;1(1):22–6.
17. Fogari R, Zoppi A, Tettamanti F, et al. B–blocer effects on plasma lipids in antihypertensive therapy. J Cardiovasc Pharmacol 1990;16(5):76–80.
18. Koning L, Merchant AT, Pogue J, et al. Waist circumference and waist–to–hip ratio as predictors of cardiovascular events: meta–regression analysis of prospective studies. European Heart Jornal 2007;28(7):850–56.


Похожие статьи


Бионика Медиа